Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This 'theranostic' approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its 'theranostic' approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the 'SEC'), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:Annie J. Cheng, CFA
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
The Home Depot, Inc. (HD) Fell Because Of Sherwin-Williams, Says Jim Cramer
We recently published . The Home Depot, Inc. (NYSE:HD) is one of the stocks Jim Cramer recently discussed. The Home Depot, Inc. (NYSE:HD) is one of the largest home improvement retailers in America. Its shares have lost 2.9% year-to-date due to persistent sluggishness in the housing market. In his previous remarks about the firm, Cramer also attributed some of the weakness surrounding The Home Depot, Inc. (NYSE:HD) to a slow gardening season. This time, he discussed the impact of Sherwin-Williams' bearish outlook for H2 2025 on the shares: 'Home Depot's up seven and my charitable trust owns that. And now I look at that and I think that's because of Horton being up and Lennar being up and Pulte being up. But that's not what references, it's Sherwin Williams. And that means that maybe it's too high.' In an earlier appearance, the CNBC TV host commented on The Home Depot, Inc. (NYSE:HD)'s link to the housing market: 'Home Depot, now here's a company that's seen as being synonymous with the housing market, and the housing market stinks. Well, not enough homes being sold, gotta be bad, right? Well, wait a second. This stock's now been in the doghouse for ages. It's also why we've been buying for the Charitable Trust. Like Costco, people don't seem to want to buy Home Depot unless it's within spitting distance of its highs. They want to buy Home Depot when it's hot. I want to buy Home Depot when it's not. Home decor They just spent $5.5 billion on GMS, a drywall, steel framing, and ceiling products distributor. In other words, in the last year, Home Depot's only improved its position in remodel and renovation while it waits for the housing market to come back. Now, why does this matter? Because you don't get many chances to buy the stock of Home Depot at a considerable discount to its high. People would rather buy Home Depot at $439, its high from last year, than $373, where it's trading now. I look at it like this: How often can you buy a quality franchise like Home Depot when it's not running, when it's not near its high? Not often.' While we acknowledge the potential of HD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Here's What Key Metrics Tell Us About Hayward Holdings (HAYW) Q2 Earnings
Hayward Holdings, Inc. (HAYW) reported $299.6 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 5.4%. EPS of $0.24 for the same period compares to $0.21 a year ago. The reported revenue represents a surprise of +4.39% over the Zacks Consensus Estimate of $287 million. With the consensus EPS estimate being $0.22, the EPS surprise was +9.09%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Hayward Holdings performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- North America (NAM) (US and Canada): $255.2 million versus the three-analyst average estimate of $242 million. The reported number represents a year-over-year change of +5.8%. Net Sales- Europe & Rest of World (E&RW): $44.4 million versus $45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.6% change. Net Sales- Europe & Rest of World (E&RW): $44.4 million versus the three-analyst average estimate of $45 million. The reported number represents a year-over-year change of +2.6%. Net Sales- North America (NAM) (US and Canada): $255.2 million compared to the $242 million average estimate based on three analysts. The reported number represents a change of +5.8% year over year. View all Key Company Metrics for Hayward Holdings here>>> Shares of Hayward Holdings have returned +5.7% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hayward Holdings, Inc. (HAYW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Ford Motor Company (F): I'm Looking For A Good Quarter, Says Jim Cramer
We recently published . Ford Motor Company (NYSE:F) is one of the stocks Jim Cramer recently discussed. The impact of tariffs on US companies and car manufacturers in particular has reversed the thesis surrounding Ford Motor Company (NYSE:F) and its rival and peer, General Motors. Ahead of the tariffs, investors appeared to be preferring GM as it managed to maintain product demand in 2024 while Ford Motor Company (NYSE:F) suffered from high warranty costs. However, exposure to the Mexican supply chain has turned the tables. Here's what Cramer said: 'They're gonna have a lot more that I think can go their way. Uh, when I was speaking to Cleveland Cliffs yesterday, to Lorenzo Goncalves. . I mean he's just talking about this is the beginning of a lot of different things. Very in flux. GM has, Ford has told me GM has much, much exposure. Versus Ford. So I'm looking for Ford to have a good quarter. By the way, Ford's going for 10, Ford's making a 20% move here. So I look to see who has the most exposure. And I've got to tell you, Ford was right when it said be careful, GM. Because everyone in the industry knows that there's a lot of companies ship a lot of stuff. Get to Allison Motor, down there in Mexico, it comes back. GM, David, it's like back and forth with the car. . .that is not what they want.' Pixabay/Public Domain While we acknowledge the potential of F as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
